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Pharmacovigilance in Pediatric 
Population
Roxana De Las Salas and Claudia Margarita Vásquez Soto
Abstract
Pharmacology in pediatric population has specific needs in pharmacovigilance. 
The lack of studies in children leads mostly to “off-label” prescribing and to an 
increased frequency of adverse drug reactions. Additionally, younger ages, male 
sex, prolonged and previous hospitalization, indication of antibiotics, and the 
number of prescribed drugs are factors associated with a higher risk of ADRs. 
Consequently, ADRs represent an additional burden of morbidity. This chapter 
will be focused on the most common adverse drug reactions in children (including 
infants and newborns), challenges, and new legislative tools in pediatric pharma-
covigilance by using the Word Health Organization global individual case safety 
report database (VigiAccess) and results from a Latin American study.
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1. Introduction
The safety of medicines in children is a worldwide problem, and the pharma-
cological characteristics of infants require a specific knowledge by health-care 
professionals. In other words, to care for children, more training and expertise are 
necessary. Likewise, the lack of clinical trials in which children are included and the 
off-label use of medications are determining factors for having more adverse drug 
reactions than usually. In ambulatory and hospital settings, it is necessary to have 
personnel with training in taking care of children.
Pharmacovigilance (PV), as was mentioned in the other chapter, “is defined as the 
science and activities relating to the detection, assessment, understanding and preven-
tion of adverse effects or any other drug-related problem” [1]. It is also proper to ensure 
that PV was born recently with the thalidomide disaster, with effects on children.
Considering the abovementioned, this chapter shows the main concepts of 
pharmacovigilance applied to the pediatric population and gives an idea of the main 
safety concerns of drugs used in the neonatology and pediatric wards and the most 
frequent adverse reactions. On the other hand, this adds new legislative tools in 
pediatric pharmacovigilance.
2. A brief history of the beginning of pharmacovigilance in pediatrics
The first example of a safety issue that led to a pharmacovigilance reflection was 
published in the British Medical Journal in 1877 by chloroform issues. The second 
problem happened in 1898 with the commercialization of diacetylmorphine, named 
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as heroin, which started to be addictive at the beginning of the 1910s (500,000 
dependent patients reported only in the US) [2]. In 1937, the use of diethylene glycol 
to solubilize sulfanilamide, without any toxic test previously studied, with a series 
34 children deaths from kidney failure (of 103 cases) [3]. The third one was at the 
beginning of the 1950s (1954), diiododiethyl of tin was added to Stalinon®, a topical 
skin product, resulting in 102 cases of deaths associated with encephalopathy, and a 
hundred patients developed severe, irreversible, neurological aftereffects [2].
During the 1960s, many children were born with phocomelia and agenesis of 
the limbs as a side effect of thalidomide. Thalidomide was marketed in 1957 as an 
over-the-counter (OTC) hypnotic/sedative and a safe drug, later used in order to 
manage nausea in pregnant women. In 1961, Widukind Lenz, a German geneticist, 
linked the serious effects to the use of thalidomide during a congress. This was later 
confirmed in the same year by William McBride, who established a 20% of rise in 
phocomelia and agenesis of the limbs malformation. The results were more than 
12,000 cases of teratogenic effects in children (not only limbs malformation) [2].
In response to the thalidomide disaster, the World Health Organization (WHO) 
formerly established its Program for International Drug Monitoring in 1968. In 
1978, it is founded the Uppsala Monitoring Centre, a WHO collaborating center 
created in order to support the mentioned program.
Therefore, a new era of pharmacovigilance was initiated by children’s big 
issues related to teratogenic effects. In other words, PV was born as a result of a 
disaster in children.
3. Key concepts of pharmacovigilance in pediatrics
According to the World Health Organization (WHO), an adverse drug reaction 
(ADR) is “a response to a drug which is noxious and unintended and which occurs 
at doses normally used in man for prophylaxis, diagnosis, or therapy of disease, or 
the modification of physiological function” [4].
In Spain, the pharmacovigilance system defines an ADR as any harmful and 
unintentional response to a medication. It not only includes harmful and involun-
tary effects derived from the authorized use of a medicine in normal doses but is 
also related to medication errors and off-label terms of the marketing authorization, 
including misuse, overdose, and abuse of the drug [5]. Terms such as side effect, 
adverse effect, undesirable effect, and collateral effect are synonymous of ADR.
The variability among pediatric population is associated with higher susceptibil-
ity for ADRs. Considering this, whenever there is an ADR, it is necessary to take 
into account not only the weight, height, and information of the medication but 
also the exact age of the child. For that reason, it is important to know the pharma-
cological differences in infants, as shown in Table 1 [6, 7].
3.1 Challenges of pharmacovigilance in pediatrics
Despite international authorities’ efforts to stimulate the notification of adverse 
drug reactions (ADRs), under-reporting is still quite common [8]. In part, this hap-
pens due to the voluntary notification system mainly. Other reasons could be related 
to problems with the ADR diagnosis, work overload of staff, and possible conflicts 
of interest [9]. Thereby, the most important challenges in PV are focused on those 
issues.
Despite the European Medicines Agency, Pharmacovigilance Risk Assessment 
Committee (PRAC) has a pediatric Committee (PDCO) that revise “all aspects 
of the risk management of the use of medicinal products”; and generate 
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recommendations of safety use of medicine in pediatrics, actually there are many 
challenges [10].
Intensive pharmacovigilance is needed in pediatric population, due to increased 
susceptibility to ADRs and predisposing factors [11, 12]. Intensive pharmacovigilance 
is defined as “the systematic monitoring of the occurrence of adverse events resulting 
from drug use during the entire length of prescription” [13]. This is the first pharma-
covigilance challenge, to achieve integration in health systems in a proactive and rou-
tinary way. The truth is that pharmacovigilance must function dynamically and based 
on the fundamental pillars of public health: protection, promotion, and prevention.
Another important challenge is to implement a mandatory reporting system, 
because in the case of adverse reactions in children, it is always important to analyze 
the reason for ADR. This is perhaps the most important challenge.
In addition, as shown in Image 1, to achieve a benefit-risk balance in pediatric 
populations, it is necessary to implement a dynamic PV cycle that allows the gain 
of knowledge and the management of risks associated with medicines in children. 
That could be an important new legislative tool in pediatric pharmacovigilance.
On the other hand, due to off-label being permitted, authorities have to demand 
from pharmacy industry the inclusion of children in clinical trial. The main reason 
for that is that if it is not ethical to include children in clinical trials, much less is to 
use a medicine that has never been prescribed or used in children population before.
Despite, PRAC-PDCO is constantly communicating about the importance 
of ADR monitoring and reporting suspected ADR in order to create signals for 
pediatric population. Some legislative tools for improving pharmacovigilance in 
pediatric population could be to promote research networks and ADR report in 
children (including pregnancy), to create networks of pediatric use of medicine and 
pharmacovigilance, to pilot new approaches to strengthen signal detection, to work 
on medication error, and to create a PRAC-PDCO collaborative working on benefit-
risk worldwide [10] (Image 2).
Physiologic characteristics Characteristics
Absorption
Gastric pH Lower bioavailability of weak acid drugs
Higher bioavailability of weak bases
Gastrointestinal motility Delayed absorption
Percutaneous absorption Higher bioavailability
Muscle absorption Variable (unknown)
Distribution
Body water Higher volume of distribution for hydrophilic drugs
Less volume of distribution for hydrophilic drugs
Protein binding Higher free fraction of drugs
Metabolism
Phase I enzyme (cytochrome (CYP) P450) Less hepatic clearance
Phase II enzyme (UGT) Less hepatic clearance. Glucuronidation does not reach 
adult levels for at least 3 years of age
Elimination
Renal excretion GFR (tubular absorption and 
secretion)
Lower renal clearance. Nephrogenesis is complete at 
34 weeks of gestation. GFR reaches adult levels by 2 years 
of age
GFR, glomerular filtration rate; UGT, UDP-glucuronosyltransferase. Source: [6, 7].
Table 1. 
Pharmacological characteristics that can condition the appearance of adverse reactions to medications.
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3.2 Importance of pharmacovigilance in children’s intensive care units
Patient safety in child intensive care units is a priority in health care, in which 
the entire interdisciplinary team has to use guidelines and protocols that attempt to 
minimize the errors that occur in clinical practice. These controls can be efficient 
and effective, but sometimes fail, and it produces an error during the prescrib-
ing or the administration of medications [14]. Due to complex diseases, critically 
ill children (newborns and infants) in intensive care units are in a higher risk of 
developing ADRs [15].
In the neonatal and pediatric intensive care units, efforts have been made to 
strengthen drug administration processes focused on improving patient identifica-
tion, drug, and dosage, through a list of checkups with a clear and timely focus on 
risk management in the use of medications [14].
Image 1. 
Significant milestones of the history of pharmacovigilance in pediatrics.
Image 2. 
Pharmacovigilance cycle. Source: Taken from: Raine J. Pharmacovigilance in Paediatric Population. The 
PRAC’s perspective EU: EMA; 2014. (10).
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Therefore, as a component of patient safety policy, in each health institution, 
this must be effectively coordinated with the pharmacovigilance system; although 
what this policy is looking for and working for is the patient safety, seen from 
the integral clinical component and from the pharmacovigilance perspective, the 
medicine and its use are taken as the central axis. Therefore, the need to efficiently 
regulate both actions is emphasized, with the aim of not affecting the duplication 
of efforts and results, in order to achieve maximum patient safety and the most 
optimal management possible on the safe use of medicines [16].
Due to ADR and inadequate practices on the use of medications which make up 
a large percentage of hospital admissions and extensive hospital days of stay, it is 
vitally important to have active pharmacovigilance, improving the education and 
communication of all risks related to medications. All health teams have to use the 
same language, and this is possible because the protocols and clinical guidelines 
established in the institutions, as well as improving the notification of errors in 
order to analyze and to improve plans [17].
4. Adverse drug reactions in children
The WHO Global Individual Case Safety Report (ICSR) database (VigiBase®), 
using spontaneous notification system, has reported ADR rates of 7.7% (268.145) 
in children from 0 to 17 years of age [18]. Nevertheless, ADR prevalence in children 
can vary due to patient characteristics, methodology used in the evaluation of the 
suspected ADR, and pharmacological treatments. In addition, ADR only can be 
classified as definitive if the medication or placebo was readministered and the 
blood concentration of the drug measured, which is not possible, even for ethical 
issues in the care of children.
Country/
study
Study ID ADR 
incidence
Age Type of study Number 
of 
patients
Type of 
service
Spain Belen 
2016 
[19]
17.00% ≤29 days 
(neonates)
Prospective 
cohort study
332 Neonatal 
ward
Mexico Vásquez-
Alvarez 
2017 
[20]
1.75% ≤18 years 
of age
Prospective 
cross-sectional
1083 Hospital 
admissions
Colombia De las 
salas 
2016 [21, 
22]
21.31% ≤5 years of 
age
Prospective 
cohort study
1056 Neonatal 
and 
pediatrics 
wards
Brazil Barbosa 
2006 
[23]
12.50% ≤16 years 
of age
Prospective 
cohort study
265 Pediatric 
ward
United 
States*
Sharek 
2006 
[24]
4.54% ≤29 days 
(neonates)
Retrospective 
cross-sectional 
study
749 NICUs
India Digra 
2015 [25]
0.36% ≤19 Prospective 
observational 
study
28,864 Pediatric 
ward
*Included one Canada neonatal care unit of 15. NICU, neonatal intensive care unit.
Table 2. 
Incidence of ADR in children from different countries around the world.
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Age/drug DM Guaifenesin Pseudoe PE BH CP DH Codeine
0–27 days 9 4 66 13 3 93 25 13
28 days to 
23 months
149 103 217 76 13 287 274 136
2–11 years 825 194 502 79 21 703 741 429
12–17 years 600 95 471 37 8 356 604 277
Total 1583 396 1256 205 45 1439 1644 855
DM, dextromethorphan; GUA, guaifenesin; pseudo, pseudoephedrine; PE, phenylephrine; BH, brompheniramine; 
CP, chlorpheniramine; DH, diphenhydramine. Source: vigiaccess.org
Table 4. 
Number of ADRs in children from UMC reports of some cold medicine.
Many studies conducted in different countries, using mostly prospective 
observational studies, have reported ADR rates ranging from 0.36 to 21.31%. This is 
described in Table 2.
4.1 Individual case safety report
Considering the importance of ADR notifications reported to the Uppsala 
Monitoring Centre (UMC), some of the drugs with greater frequency of use or with 
relevant aspects of safety in children have been selected. As nonsteroidal anti-
inflammatory drugs (NSAIDs), anticonvulsant, opioids, and certain cold medicines 
are frequently used and have relevant issues in medicine safety in children, this 
section presents the results of the World Health Organization global individual case 
safety report database (VigiAccess).
The ADR frequency report for NSAIDs is variable. Ibuprofen is the drug with the 
highest ADR report in children. It could be due to the fact that it is one of the most 
used drugs in this population. The comparison of other NSAID ADRs is presented 
in Table 3.
Different studies [26, 27] and safety reports [28–30] indicate that cold medicines 
and opioids may represent risks of ADRs, particularly in younger children. As it is 
shown in Table 4, the majority of UMC reports are associated to diphenhydramine 
and dextromethorphan. Codeine reports are still growing.
Age/drug Ibuprofen ASA* Diclofenac Naproxen Indomethacin Piroxicam
0–27 days 416 122 53 36 180 9
28 days to 
23 months
3113 533 195 263 107 16
2–11 years 12,428 2196 986 922 144 67
12–17 years 6016 1741 2091 1622 231 184
Total 21,973 4592 3325 2843 662 276
Source: vigiaccess.org. Accessed: 08-15-2018.
*Acetylsalicylic acid. NSAIDs, nonsteroidal anti-inflammatory drugs.
Table 3. 
NSAID ADRs in children.
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5. A Latin American experience in ADR prospective study
5.1 Study design and participants
A prospective observational cohort study based on intensive pharmacovigilance 
was conducted from June to December 2013 in two general pediatric wards located in a 
city of the Colombian Caribbean Coast. One hospital was private and included 20 bed 
capacity units, from which isolation beds are assigned on a need basis. The other hos-
pital was public with 29 bed capacity units, two of which are used for isolated patients. 
Both hospitals admit children between the neonatal period and 17 years of age.
This study included 1056 pediatric patients of ≤5 years of age (including neo-
nates) without ADRs which were hospitalized at least 24 hours and had at least one 
prescribed medication. Researchers followed the patients until discharge. All par-
ents authorized children participation and signed a consent. Patients were excluded 
if they were admitted only for taking diagnostic test or referred from other institu-
tions. In addition, side effects associated with the administration of intravenous 
solutions, contrast media, nutraceuticals, and topical products were not monitored.
5.2 Data collection
Data collection was conducted by a clinical nurse who was trained in ADR detec-
tion. Daily visits to the wards were conducted. The instrument had two sections; the 
first one contained a sociodemographic variables, medical history, and information 
about previous medicines. The second one was an adaptation of the Yellow Card 
Scheme. All data from nursing, medical, and clinical laboratory test records were 
evaluated in order to detect suspected ADRs. A suspected ADR was defined as “any 
deviation of the expected clinical status (signs, symptoms and other clinical and 
laboratory findings)” [31].
The modified Schumock and Thornton criteria [32] were used to evaluate 
preventability. Naranjo’s algorithm was employed to evaluate the temporal relation-
ship and the biological/pharmacological plausibility between drug exposure and 
suspected ADR [33], while the severity was judged using modified Hartwig and 
Siegel Assessment Scale [34]. The team employed for analyzing the aspects was 
multidisciplinary (a pharmacist, a nurse, a pharmacologist, and a pediatrician).
5.3 Statistical analysis
A descriptive analysis of the variables was conducted. A crude bivariate relative 
risk (RR) and 95% confidence interval (CI) were estimated between the presence 
or absence of ADRs (dependent variable) and other variables. A chi-square test 
(p < 0.05) was also done between the dependent variable and the other one.
5.4 Incidence and characteristics of ADRs
Due to physiological and pharmacological differences between neonates and 
children of other ages, the results of this research are presented in a comparative way.
Two hundred seventy-nine ADRs were detected in 225 children. The cumula-
tive incidence of ADRs was 21.31% (225/1056). Separately, neonate’s incidence was 
27.4% (78/284) and ≤5 years of age was 19.0% (147/772) [21, 22].
In neonates, 0.81% (1) of the ADRs were classified as definite (certain), 82.93% 
(102) probable, and 16.26% (20) possible. About 98.37% (121) were not preventable 
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and 1.63% (2) preventable. About 9.75% (12) of the ADRs were severe, 31.71% (39) 
moderate, and 58.74% (72) mild.
On the other hand, in children ≤5 years of age, 0.64% (1) of the ADRs were clas-
sified as definite (certain), 98.08% (153) probable, and 1.28% (2) possible. About 
98.72% (154) were not preventable and 1.28% (2) preventable. In terms of severity, 
66.03% (103) of the ADRs were mild and 33.97% (53) moderate.
The comparison is shown in Table 5, in which it shows higher rates of severe 
ADRs in neonates. It may be related with the complex treatment established in 
neonatal intensive care unit (NICU).
The most affected organ system in neonates was the hematologic. In children 
≤5 years of age, the most affected organ system was digestive. The entire list is 
detailed in Table 6. In all cases, ADR treatment was the responsibility of physicians.
The therapeutic group that most frequently produced ADRs was systemic antibi-
otics, in both groups, neonates and children. This information is detailed in Table 7. 
This is mainly due to the high use of this group of drugs in children.
5.5 Factors associated with ADRs
The mean gestational age in neonates with ADRs was 34.5 weeks compared with 
37.0 (p = 0.003) who did not have. Additionally, preterm newborns were 2.30 more 
likely to have an ADR compare with term (95% CI 1.31–4.01, p = 0.003). The mean 
of days of hospitalization in neonates who had ADRs was 18.5, in comparison with 
7.0. Having a hospital stay less than ≤8 days is related with the nonappearance of 
ADR (RR = 0.076, 95% CI 0.037–0.156, p = 0.000) [21].
The mean age of children ≤5 years of age that developed ADRs was similar 
between both groups, the ones who had ADRs and the ones did not showed any. 
However, ADR frequency was higher in children under 2 years of age (12.70%) than 
in children with 2 or more years of age (6.30%). Male patients were more likely to 
develop ADRs (RR = 1.66; 95% CI 1.22–2.25, p = 0.001) than female [22].
The mean length of hospitalization in children ≤5 years of age who had ADRs 
was higher (7.1 days ±5.2) than those who did not show ADRs (5.3 days ±2.6, 
p = <0.001) [22]. The mean of prescribed medicines in children with ADRs was 
Characteristics Neonatal age n = 284 Children ≤5 years of age  
n = 772
N % N %
Imputability (Naranjo’s algorithm)
Definite (certain) 1 0.81 1 0.64
Probable 102 82.93 153 98.08
Possible 20 16.26 2 1.28
Severity (Hartwig and Siegel scale)
Severe 12 9.75 0 0
Moderate 39 31.71 53 33.97
Mild 72 58.54 103 66.03
Preventability
Preventable 2 1.63 2 1.28
Not preventable 121 98.37 154 98.72
Table 5. 
Characteristics of ADRs in Colombian children.
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higher than those who did not show any (mean 5.0 ± 2.5 vs. 3.9 ± 2.4 drugs) 
(p = <0.001). Similarly, the number of prescribed systemic antibiotics in children 
with ADRs was also higher than in those who were not prescribed any (mean 
2.0 ± 0.5 vs. 1.0 ± 0.5) (p = <0.001). The use of systemic antibiotics was correlated 
with a higher risk of ADRs (RR = 1.82 (95% CI 1.17–2.82, p = 0.005)) than those 
who did not use an antibiotic (Table 4). About 1.5% (12) of patients with ADRs 
reported previous ADRs [22].
6. Discussion
We followed a cohort of 1056 hospitalized patients, among neonates and chil-
dren ≤5 years of age. We identified an ADR incidence of 21.3%, which is higher 
than Jimenez et al. [35]. These results demonstrate that children are particularly 
susceptible to ADRs. A Cuban Research which included patients under 18 years of 
age found that the age range most affected by ADRs was between 2 and 11 years 
Organic system affected Neonatal age n = 284 Children ≤5 years of age n = 772
N % N %
Hematologic 42 34.15 2 1.28
Digestive 41 33.33 100 64.1
Renal 12 9.76 4 2.56
Integumentary 6 4.88 19 12.19
Cardiovascular 3 2.44 21 13.46
Others 19 15.44 10 6.41
Total of ADR 123 100 156 100
Table 6. 
Organic system affected in neonates and children with ADRs.
ATC code Neonatal age 
n = 284
Children ≤5 years of age 
n = 772
N % N %
Anti-infectives for systemic use 99 80.49 110 70.51
Respiratory system 9 7.31 25 16.03
Systemic hormonal preparations* 1 0.81 7 4.49
Nervous system 2 1.63 8 5.13
Cardiovascular system 3 2.44 1 0.64
Blood and blood-forming organs 2 1.63 1 0.64
Alimentary tract and metabolism 0 0 4 2.56
Others 7 5.69 0 0
Total 123 100 156 100
ATC, anatomical therapeutic chemical classification.
*Excluding sex hormones and insulins.
Table 7. 
ADRs presented by children.
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of age [36]. But we only included patients ≤5 years of age. Children ages were 
divided as <2 years and ≥2 years of age, due to biological variability. Males were 
more often affected by ADRs than females, similar to the WHO ICSR database 
(VigiBase ®), in which ADRs were primarily presented in males [18]. However, 
other studies have revealed higher ADRs rate in females [36, 37].
The mean of days of hospitalization in neonates who had ADRs was 18.5, in 
comparison with 7.0. The average length of hospitalization in older children was 
7.1 days. This difference might be due to differences in neonates and children 
patients. The mean number of prescribed medicines in children with ADRs was 
similar to European and non-European countries who have reported an average 
number higher than 5 [33].
Respiratory drugs and systemic antibiotics were the therapeutic groups mostly 
associated with ADR incidence in both neonates and children. As noted, respiratory 
drugs and systemic antibiotics are not only the most prescribed class of drugs for 
hospitalized children but also the ones that usually cause ADRs. The most commons 
ADRs linked to systemic antibiotics were digestive for older children, while hemato-
logic were for neonates. Similar findings were reported by Belen-Rivas et al. [19].
Most of the ADRs found in our study were mild. These results differ with the 
findings of Shamna et al. [39], who found that moderate ADRs were the most 
common. According with Naranjo’s algorithm, the majority of ADRs were classified 
as probable; also Belen-Rivas [19] reported that the majority of ADRs were prob-
able. The evaluation of ADRs is predisposed by the definitions, the methodology of 
detection, classification, and the study setting included.
The main limitation of this study was the determination of imputability of 
adverse events. Regardless of patient daily visits, only 0.81% of neonates and 0.64% 
of older children were categorized as definite ADRs. Naranjo’s algorithm determines 
an ADR as definite when the drug is readministered or a placebo is administered 
and the drug serum level lab tests are carried out. In most cases, for ethical reasons, 
these are not feasible. Likewise, if a suspected ADR is detected, in most of the cases, 
the drug is ceased, which limits the ability to evaluate all the criteria for imput-
ability. This study was purely observational, and no intervention was conducted on 
patient’s treatment.
Even though we did not estimate a sample size due to difficulties in establishing 
the general population, an observation period of 6 months permitted us to measure 
an ADR incidence.
7. Conclusion
ADRs are common among inpatient neonates and children. In neonates, hav-
ing less than ≤8 days of hospitalization is linked with the nonappearance of ADRs 
(RR = 0.076, 95% CI 0.037–0.156, p = 0.000). In children, males are more likely to 
develop ADRs (RR = 1.66; 95% CI 1.22–2.25, p = 0.001) than females. Even when 
in neonates, it is not a significant RR; males have higher rates of occurrence than 
females. Systemic antibiotics are correlated with a higher risk of ADRs (RR = 1.82 
(95% CI 1.17–2.82, p = 0.005) in children. All these findings mean that ADR repre-
sents an additional burden of morbidity and risk for pediatric patients, particularly 
in those who used several medicines.
Pharmacovigilance in pediatric population needs to be reinforced. It is necessary 
to develop a proactive pharmacovigilance and patient safety programs with a focus 
in risk analysis and management, in which ADR reporting should be mandatory. 
This measure might help us make our health-care systems safer, especially for 
children, in which this topic must be further investigated.
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For succeeding in ADR detection, it is important to have a team conformed by phy-
sicians, nurses, pharmacists, and others (according to the health service). In addition, 
it should be noted that, due to the role nurses play in the administration and monitor-
ing of therapy, they have a privileged position to detect drug effects, including ADRs.
In order to prevent ADRs, it is advisable to generate strategies that are aimed at 
improving drug administration safety protocols.
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Appendices and nomenclature
ADR adverse drug reaction
OTC over the counter
WHO World Health Organization
NICU neonatal intensive care unit
UMC Uppsala Monitoring Centre
NSAIDs non-steroidal anti-inflammatories
Pharmacovigilance
12
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Roxana De Las Salas1* and Claudia Margarita Vásquez Soto2
1 Universidad del Norte, Barranquilla, Colombia
2 Hospital Universidad del Norte, Barranquilla, Colombia
*Address all correspondence to: rdelassalas@uninorte.edu.co
13
Pharmacovigilance in Pediatric Population
DOI: http://dx.doi.org/10.5772/intechopen.82253
[1] World Health Organization. The 
importance of pharmacovigilance. 
Safety Monitoring of Medicinal 
Product. United Kingdom: World Health 
Organization; 2002. Available from: 
http://apps.who.int/medicinedocs/pdf/
s4893e/s4893e.pdf?ua=1 [Accessed: 
2018-06-30]
[2] Caron J, Rochoy M, Gaboriau 
L, Gautier S. The history of 
pharmacovigilance. Therapie. 
2016;71(2):129-134
[3] Wax PM. Elixirs, diluents, and the 
passage of the 1938 Federal Food, Drug 
and Cosmetic Act. Annals of Internal 
Medicine. 1995;122(6):456-461
[4] The Uppsala Monitoring 
Centre. Glossary of terms used in 
Pharmacovigilance. Uppsala: UMC, 
2011. Available from: http://who-umc.
org/Graphics/24729.pdf [Accessed: 
2018-06-20]
[5] AEMPS. Information for 
Notifications of Suspected Adverse 
Drug Reactions by Health Professionals. 
Spain: AEMPS; 2015. Available from: 
https://www.aemps.gob.es/vigilancia/
medicamentosUsoHumano/SEFV-H/
NRA-SEFV-H/notificaSospechas-
RAM-profSanitarios.htm [Accessed: 
2018-06-30]
[6] Lu H, Rosenbaum S. Developmental 
pharmacokinetics in pediatric 
populations. The Journal of Pediatric 
Pharmacology and Therapeutics. 
2014;19(4):262-276
[7] O’Hara K, Wright IMR, Schneider JJ, 
Jones AL, Martin JH. Pharmacokinetics 
in neonatal prescribing: Evidence 
base, paradigms and the future. British 
Journal of Clinical Pharmacology. 
2015;80(6):1281-1288
[8] Hennessy S, Strom BL. PDUFA 
reauthorization—Drug safety’s 
golden moment of opportunity? 
New England Journal of Medicine. 
2007;356:1703-1704
[9] Vallano A, Cereza G, Pedròs 
C, Agustí A, Danés I, Aguilera C, 
et al. Obstacles and solutions for 
spontaneous reporting of adverse 
drug reactions in the hospital. British 
Journal of Clinical Pharmacology. 
2005;60(6):653-658
[10] Raine J. Pharmacovigilance in 
Paediatric Population. The PRAC’s 
perspective EU: EMA; 2014
[11] Thiesen S, Conroy EJ, Bellis JR, 
Bracken LE, Mannix HL, Bird KA, et 
al. Incidence, characteristics and risk 
factors of adverse drug reactions in 
hospitalized children—A prospective 
observational cohort study of 
6,601 admissions. BMC Medicine. 
2013;11(1):1-10
[12] Temple ME, Robinson RF, Miller JC, 
Hayes JR, Nahata MC. Frequency and 
preventability of adverse drug reactions 
in paediatric patients. Drug Safety. 
2004;27(11):819-829
[13] Pan American Health Organization. 
Good pharmacovigilance practices 
for the Americas. PANDRH Technical 
Document N° 5. Washington, DC: 
PAHO; 2011. Available from: http://
apps.who.int/medicinedocs/documents/
s18625en/s18625en.pdf Accessed: 
2018-06-30
[14] Turner MA, Hill H. 
Pharmacovigilance in neonatal intensive 
care. In: Mimouni F, van den Anker JN, 
editors. Neonatal Pharmacology and 
Nutrition Update. 18. Basel: Karger; 
2015. pp. 28-40
[15] Du W, Lehr VT, Lieh-Lai M, Koo 
W, Ward RM, Rieder MJ, et al. An 
algorithm to detect adverse drug 
reactions in the neonatal intensive care 
References
Pharmacovigilance
14
unit. Journal of Clinical Pharmacology. 
2013;53(1):87-95
[16] Healthcare Ministry. Improving 
Patient Safety in Medicines Use. 
Colombia: Healthcare Ministry; 2010. 
Available from: https://www.minsalud.
gov.co/sites/rid/Lists/BibliotecaDigital/
RIDE/DE/CA/seguridad-en-la-
utilizacion-de-medicamentos.pdf 
[Accessed: 2018-06-30]
[17] Sharma B, Bhattacharya A, Gandhi 
R, Sood J, Rao B. Pharmacovigilance 
in intensive care unit—An overview. 
Indian Journal of Anaesthesia. 
2008;52:373
[18] Star K, Noren GN, Nordin K, 
Edwards IR. Suspected adverse 
drug reactions reported for children 
worldwide: an exploratory study 
using VigiBase. Drug Safety. 
2011;34(5):415-428
[19] Belén-Rivas A, Arruza L, Pacheco E, 
Portoles A, Diz J, Vargas E. Adverse drug 
reactions in neonates: A prospective 
study. Archives of Disease in Childhood. 
2016;101(4):371-376
[20] Vázquez-Alvarez AO, Brennan-
Bourdon LM, Rincón-Sánchez AR, 
Islas-Carbajal MC, Huerta-Olvera SG. 
Improved drug safety through intensive 
pharmacovigilance in hospitalized 
pediatric patients. BMC Pharmacology 
& Toxicology. 2017;18:79
[21] De las Salas R, Díaz-Agudelo D. 
Reacciones adversas a medicamentos 
en neonatos hospitalizados en unidades 
de cuidado intensivo neonatal en 
Barranquilla, Colombia. Biomédica. 
2017;37:33-42
[22] De las salas R, Díaz-Agudelo 
D, Burgos-Flórez FJ, Vaca C, 
Serrano-Meriño DV. Adverse drug 
reactions in hospitalized colombian 
children. Colombia Médica. 
2016;47(3):2016
[23] dos Santos DB, Coelho HL. 
Adverse drug reactions in hospitalized 
children in Fortaleza, Brazil. 
Pharmacoepidemiology and Drug 
Safety. 2006;15(9):635-640
[24] Sharek PJ, Horbar JD, Mason W, 
Bisarya H, Thurm CW, Suresh G, et 
al. Adverse events in the neonatal 
intensive care unit: development, 
testing, and findings of an NICU-
focused trigger tool to identify harm 
in North American NICUs. Pediatrics. 
2006;118(4):1332-1340
[25] Digra KK, Pandita A, Saini GS, 
Bharti R. Pattern of adverse drug 
reactions in children attending the 
department of pediatrics in a tertiary 
care center: A prospective observational 
study. Clinical Medicine Insights 
Pediatrics. 2015;9:73-78
[26] Paul IM, Reynolds KM, Green JL. 
Adverse events associated with opioid-
containing cough and cold medications 
in children. Clinical Toxicology (Phila). 
2018:1-3
[27] Etminan M, Nouri MR, Sodhi M, 
Carleton BC. Dentists’ prescribing 
of analgesics for children in British 
Columbia. Canada. Journal of 
the Canadian Dental Association. 
2017;83:h5
[28] FDA. FDA Drug Safety 
Communication: FDA Requires 
Labeling Changes for Prescription 
Opioid Cough and Cold Medicines 
to Limit their Use to Adults 18 Years 
and Older. USA: FDA; 2018. Available 
from: https://www.fda.gov/Safety/
MedWatch/SafetyInformation/
SafetyAlertsforHumanMedical 
Products/ucm590435.htm [Accessed: 
2018-06-30]
[29] FDA. FDA Drug Safety 
Communication: FDA Restricts Use of 
Prescription Codeine Pain and Cough 
Medicines and Tramadol Pain Medicines 
15
Pharmacovigilance in Pediatric Population
DOI: http://dx.doi.org/10.5772/intechopen.82253
in Children; Recommends Against Use 
in Breastfeeding Women. USA: FDA; 
2017. Available from: https://www.fda.
gov/Drugs/DrugSafety/ucm549679.htm 
[Accessed: 2018-06-30]
[30] FDA. FDA Drug Safety 
Communication: FDA Evaluating 
the Potential Risks of Using Codeine 
Cough-and-Cold Medicines in Children. 
USA: FDA; 2015. https://www.fda.gov/
Drugs/DrugSafety/ucm453125.htm. 
Available from: [Accessed: 2018-06-30]
[31] International Conference on 
Harmonisation (ICH). Post-approval 
Safety Data Management: Definitions 
and Standards for Expedited Reporting 
E2D; 2003. http://www.ich.org/
fileadmin/Public_Web_Site/ICH_
Products/Guidelines/Efficacy/E2D/
Step4/E2D_Guideline.pdf [Accessed: 
2018-04-30]
[32] Schumock GT, Thornton JP. 
Focusing on the preventability of 
adverse drug reactions. Hospital 
Pharmacy. 1992;27(6):538
[33] Naranjo C, Busto U, Sellers E, 
Sandor P, Ruiz I, Roberts E, et al. A 
method for estimating the probability 
of adverse drug reactions. Clinical 
Pharmacology & Therapeutics. 
1981;30(2):239-245
[34] Hartwig SC, Siegel J, Schneider PJ. 
Preventability and severity assessment 
in reporting adverse drug reactions. 
American Journal of Hospital Pharmacy. 
1992;49(9):2229-2232
[35] Jimenez R, Smith A, Carleton 
B. New ways of detecting ADRs 
in neonates and children. 
Current Pharmaceutical Design. 
2015;21(39):5643-5649
[36] Furones Mourelle JA, Cruz Barrios 
MA, López Aguilera ÁF, Martínez 
Núñez D, Alfonso Orta I. Reacciones 
adversas por antimicrobianos en niños 
de Cuba. Revista Cubana de Medicina 
General Integral. 2015;31(2):205-216
[37] Li H, Guo X-J, Ye X-F, Jiang H, 
Du W-M, Xu J-F, et al. Adverse drug 
reactions of spontaneous reports in 
Shanghai pediatric population. PLoS 
One. 2014;9(2):e89829
[38] Rashed A, Wong IK, Cranswick 
N, Tomlin S, Rascher W, Neubert 
A. Risk factors associated with 
adverse drug reactions in hospitalised 
children: International multicentre 
study. European Journal of Clinical 
Pharmacology. 2012;68(5):801-810
[39] Shamna M, Dilip C, Ajmal M, 
Linu Mohan P, Shinu C, Jafer CP, et al. 
A prospective study on adverse drug 
reactions of antibiotics in a tertiary care 
hospital. Saudi Pharmaceutical Journal. 
2014;22(4):303-338
